Stocks Finish Higher as Core PCE Prices Match Expectations

US equities advanced on Friday, propelled by stronger-than-expected August personal spending and core PCE inflation aligning with forecasts, reinforcing market expectations for potential Fed rate cuts, with an 88% chance priced in for a 25 bp reduction at the next FOMC meeting. Sector-specific tailwinds included semiconductor stocks on proposed domestic manufacturing incentives, pharmaceuticals benefiting from tariff interpretations, and energy producers amid rising crude prices, alongside robust Q3 corporate earnings expectations. Gains were partially offset by a surprising drop in US consumer sentiment and hawkish comments from Richmond Fed President Barkin, while Treasury yields saw modest losses on the strong spending data.

Analysis

US equity indexes posted gains on Friday, primarily driven by macroeconomic data that reinforced expectations for Federal Reserve easing. August personal spending rose a stronger-than-expected +0.6% month-over-month, while the August core PCE price index, the Fed's preferred inflation gauge, met consensus at +2.9% year-over-year. This combination of resilient consumption and in-line inflation has solidified market pricing for a 25 basis point rate cut at the October FOMC meeting, with an 88% probability priced in. This bullish sentiment, however, is tempered by conflicting signals, including a surprise downward revision of the University of Michigan's September consumer sentiment index to a four-month low of 55.1 and slightly hawkish commentary from Richmond Fed President Tom Barkin. The corporate earnings outlook provides a supportive backdrop, with projected Q3 S&P 500 earnings growth at +6.9% and 22% of companies issuing guidance above analyst expectations. Sector performance was heavily influenced by policy news; semiconductor stocks like GlobalFoundries (+7%) and Intel (+4%) rallied on a proposed plan to boost domestic manufacturing, while pharmaceutical firms such as Eli Lilly (+1%) advanced on an interpretation that drug tariffs would benefit US-based production. Conversely, Concentrix (CNXC) fell over 13% on weak guidance, and RH (RH) declined 4% on tariff threats, highlighting significant stock-specific dispersion amidst the broader market upswing.

Key Decisions for Investors

• Investors should recognize the market's reliance on the Fed pivot narrative, supported by in-line PCE data, but remain cautious of potential volatility from weakening consumer sentiment and the political risk of a government shutdown.
• Consider overweighting sectors with direct policy tailwinds, such as US semiconductor manufacturers (INTC, GFS) and pharmaceutical companies with domestic production, while scrutinizing companies exposed to new tariffs, like RH.
• Given the sharp divergence in individual stock performance based on fundamentals, such as Concentrix's weak guidance versus Electronic Arts' takeover report, prioritize bottom-up analysis to identify alpha opportunities and avoid company-specific risks.